Related Experiment Video

Updated: May 30, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines

L Gervot1, V Carrière, P Costet

  • 1INSERM U 75, CHU Necker, Université René Descartes, 156 rue de Vaugirard, 75730 Paris Cedex 15, France.

Environmental Toxicology and Pharmacology
|July 26, 2011
PubMed

Insights

This study found that CYP3A5 is the primary CYP3A isoform in the human colon, with no induction by rifampicin. Colonic cell lines HT29 and Caco2 serve as useful models for studying xenobiotic metabolism.

Area of Science:

  • Pharmacogenomics
  • Gastroenterology
  • Drug Metabolism

Background:

  • Cytochrome P450 3A (CYP3A) enzymes are crucial for drug metabolism, primarily found in the liver and small intestine.
  • Limited information exists regarding the specific CYP3A isoforms (CYP3A4, CYP3A5, CYP3A7) and their inducibility within the human colon.

Purpose of the Study:

  • To investigate the expression and inducibility of CYP3A isoforms in the human colon.
  • To compare CYP3A expression and inducibility in human colonic tissue with established cell line models (HT29 and Caco2).

Main Methods:

  • Analysis of CYP3A protein and mRNA expression in human colonic tissue and cell lines.
  • Utilized immunoblotting, isoelectric focusing, and reverse transcription-polymerase chain reaction (RT-PCR).
  • Assessed the effect of rifampicin treatment on CYP3A expression in patients and cell lines.

Main Results:

  • CYP3A5 was identified as the predominant CYP3A isoform at both protein and mRNA levels in the human colon and cell lines.
  • Rifampicin administration did not alter CYP3A expression in either human colonic samples or the studied cell lines.
  • HT29 and Caco2 cell lines demonstrated consistent CYP3A expression and inducibility patterns.

Conclusions:

  • CYP3A5 is the main isoform responsible for CYP3A activity in the human colon.
  • The human colonic cell lines HT29 and Caco2 are suitable in vitro models for investigating xenobiotic metabolism in the colon.
  • CYP3A expression in the colon is not inducible by rifampicin.

More Related Videos

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium07:20

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Published on: April 9, 2019

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...